Arvinas Inc logo

ARVN - Arvinas Inc News Story

$63.63 0.5  0.8%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £2.23bn
Enterprise Value £1.77bn
Revenue £15.1m
Position in Universe 1856th / 6858

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

Mon 5th April, 2021 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210405:nGNX9F51WN&default-theme=true


NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:
ARVN), a clinical-stage biotechnology company creating a new class of drugs
based on targeted protein degradation, today announced two upcoming
presentations at the American Association for Cancer Research (AACR) Annual
Meeting 2021, which will be held virtually from April 10-15, 2021 and May
17-21, 2021. These presentations will describe the discovery of Arvinas’ two
clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first
disclosures of their structures.

Details for the presentations are as follows:

Title: Discovery of ARV-110, a first in class androgen receptor degrading
PROTAC® for the treatment of men with metastatic castration resistant
prostate cancer
Date and Time: April 11, 2021 from 2:05 PM - 2:15 PM ET
Presenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal
Chemistry at Arvinas
Session Title: New Therapeutics Targeting Molecular Drivers in Cancer

Title: The discovery of ARV-471, an orally bioavailable estrogen receptor
degrading PROTAC® for the treatment of patients with breast cancer
Date and Time: April 11, 2021 from 2:20 PM - 2:30 PM ET
Presenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal
Chemistry at Arvinas 
Session Title: New Therapeutics Targeting Molecular Drivers in Cancer

Abstracts will be available for registered attendees on the AACR website
(https://www.globenewswire.com/Tracker?data=ffbPMbBPhZ9S9p-3lEbDnUUdo474YGISY6ppcfUXDVw4B1BmhffflzTwGuUFhYtXBuDntykfy46lY9xBFCCPX3uqldiXklAKl0ul563t-zlYYUADdMXEhYGysH9IYDHl)
beginning on April 9, 2021.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving
the lives of patients suffering from debilitating and life-threatening
diseases through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras,
or PROTAC® targeted protein degraders, that are designed to harness the
body’s own natural protein disposal system to selectively and efficiently
degrade and remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated and
“undruggable” targets, the company has two clinical-stage programs:
ARV-110 for the treatment of men with metastatic castrate-resistant prostate
cancer; and ARV-471 for the treatment of patients with locally advanced or
metastatic ER+/HER2- breast cancer. For more information, visit
www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations 
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/01c438aa-c5bc-4cf7-aea3-ee40d0972b17)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.